A two-stage AI model predicting pathological complete response to neoadjuvant therapy in breast cancer and transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays'gene selection constraints are developed.
Jungkyu Park, D. Biswas, J. Cappadona et al.· 0 citations
BACKGROUND
Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive disease. More recently, antibody-drug conjugates (ADCs), established...
G. B. Silva, A. Simões, R. L. Nohmi et al.· Critical reviews in oncology...· 0 citations
PURPOSE OF REVIEW
Antibody-drug conjugates (ADCs) have rapidly advanced from later-line salvage therapy into first-line metastatic and curative perioperative settings. This review appraises recent practice-changing data that collectively redefined treatment standards across Human epidermal growth factor receptor 2 (HER...
Nicole Odzer, P. Tarantino· Current Opinion in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.